Sonrotoclax

• CAT Number: I042005
• CAS Number: 2383086-06-2
• Molecular Formula: C49H59N7O7S
• Molecular Weight: 890.10
• Purity: ≥95%
• Synonyms: N-[4-[(4-hydroxy-4-methylcyclohexyl)methylamino]-3-nitrophenyl]sulfonyl-4-[2-[(2S)-2-(2-propan-2-ylphenyl)pyrrolidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
• InChI: InChI=1S/C49H59N7O7S/c1-32(2)39-7-4-5-8-40(39)43-9-6-22-55(43)36-28-49(29-36)19-23-54(24-20-49)35-10-12-41(45(26-35)63-37-25-34-16-21-50-46(34)52-31-37)47(57)53-64(61,62)38-11-13-42(44(27-38)56(59)60)51-30-33-14-17-48(3,58)18-15-33/h4-5,7-8,10-13,16,21,25-27,31-33,36,43,51,58H,6,9,14-15,17-20,22-24,28-30H2,1-3H3,(H,50,52)(H,53,57)/t33?,43-,48?/m0/s1
• InChIKey: ZQTKOYMWCCSKON-HCWAPQBJSA-N
• SMILES: CC(C)C1=CC=CC=C1C2CCCN2C3CC4(C3)CCN(CC4)C5=CC(=C(C=C5)C(=O)NS(=O)(=O)C6=CC(=C(C=C6)NCC7CCC(CC7)(C)O)[N+](=O)[O-])OC8=CN=C9C(=C8)C=CN9

Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines[1].
Sonrotoclax (compound 1; 5-50 mg/kg; p.o.; daily, for 42 d; female NCG mice with acute lymphoblastic leukemia (ALL) xenografts) has antineoplastic activity and inhibits tumor growth[1].

Reference

[1]. Nan HU, et, al. Methods of cancer treatment using bcl-2 inhibitor. WO2021110102A1.